Xenotech Llc

XenoTech, LLC is dedicated to providing services and products for assessing the safety of xenobiotics intended for human consumption. We specialize in the development and application of in vitro techniques for examining the metabolism of drugs and other chemicals for pharmaceutical firms, chemical companies, academic institutions, and regulatory agencies. XenoTech's products and services are designed to provide pre-clinical safety information of the type currently recommended by the United States Food and Drug Administration to predict inter-individual variability in drug safety and efficacy, and to predict or explain adverse drug-drug interactions.

XenoTech specializes in drug metabolism research, particularly cytochrome P450-related technology. XenoTech maintains an active research and development program so that it can continue to provide leading-edge technology for the study of xenobiotics.

XenoTech is majority owned and managed by Dr. Andrew Parkinson, who is an internationally recognized scientist in the field of cytochrome P450 research. Dr. Parkinson and XenoTech's scientists have consulted for over 40 companies or regulatory agencies worldwide. The peer-reviewed results of Dr. Parkinson and XenoTech's research have been extensively published (see bibliography). Many of XenoTech's scientists have been involved in in vitro metabolism research for a decade. As of May 1999, XenoTech has five Ph.D. study directors and 22 scientists that are focused upon phase I metabolism. Research conducted by XenoTech's scientists has been instrumental in regulatory approval of two of the top 10 selling drugs worldwide.